Phase II Trial of Sequentially Administered Cisplatin, Cyclophosphamide and Doxorubicin for Urothelial Tract Tumors
Authors:
- 1 October 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 130 (4) , 681-684
Abstract
A total of 32 patients with urothelial tract tumors, 31 of whom had bidimensionally measurable disease parameters, underwent sequential intravenous administration of 70 mg./m.2 cisplatin, 250 mg./m.2 cyclophosphamide and 45 mg./m.2 doxorubicin on days 1 to 3 every 3 to 4 weeks. Of these patients 28 (88 per cent) were treated adequately, including 13 (46 per cent, 95 per cent confidence limits of 28 to 64 per cent) who achieved a complete (2) or partial (11) remission. Almost all remissions occurred within 1 to 3 weeks and persisted for a median duration of 8 months (range 4 to 16 months), with 5 patients responding for 1 or more years. Responders lived significantly longer than nonresponders, with a median of 91 versus 38 weeks, respectively (p less than 0.001). The over-all response rate with this 3-drug combination was not statistically different from that which has been observed in previously untreated, selected patients given cisplatin only. When the results of the 3-drug combination (92 responses in 202 patients) are compared to those of cisplatin alone (85 responses in 255 patients) the 3-drug regimen is statistically superior (p less than 0.002).Keywords
This publication has 5 references indexed in Scilit:
- The Management of Advanced Bladder CarcinomaJournal of Urology, 1981
- Combination Chemotherapy (CISCA) for Advanced Urinary Tract CarcinomaJAMA, 1977
- Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literatureCancer, 1977
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958